Log In
BCIQ
Print this Print this
 

R348

  Manage Alerts
Collapse Summary General Information
Company Rigel Pharmaceuticals Inc.
DescriptionTopical ophthalmic janus kinase (JAK) and spleen tyrosine kinase (SYK) inhibitor
Molecular Target Janus kinase (JAK) ; Spleen tyrosine kinase (SYK)
Mechanism of ActionJanus kinase-3 (JAK-3) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today